These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. Kunchur R, Need A, Hughes T, Goss A. J Oral Maxillofac Surg; 2009 Jun; 67(6):1167-73. PubMed ID: 19446200 [Abstract] [Full Text] [Related]
4. Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates. Lazarovici TS, Mesilaty-Gross S, Vered I, Pariente C, Kanety H, Givol N, Yahalom R, Taicher S, Yarom N. J Oral Maxillofac Surg; 2010 Sep; 68(9):2241-7. PubMed ID: 20728033 [Abstract] [Full Text] [Related]
5. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. American Society for Bone and Mineral Research Task Force on Osteonecrosis of the Jaw, Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E. J Oral Maxillofac Surg; 2008 Jun; 66(6):1320-1; author reply 1321-2. PubMed ID: 18486811 [No Abstract] [Full Text] [Related]
6. Bisphosphonates and bisphosphonate induced osteonecrosis. Sawatari Y, Marx RE. Oral Maxillofac Surg Clin North Am; 2007 Nov; 19(4):487-98, v-vi. PubMed ID: 18088900 [Abstract] [Full Text] [Related]
8. Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws. Kwon YD, Kim DY, Ohe JY, Yoo JY, Walter C. J Oral Maxillofac Surg; 2009 Dec; 67(12):2644-8. PubMed ID: 19925985 [Abstract] [Full Text] [Related]
9. Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: can they be utilized as risk markers? Kwon YD, Ohe JY, Kim DY, Chung DJ, Park YD. Clin Oral Implants Res; 2011 Jan; 22(1):100-5. PubMed ID: 20946206 [Abstract] [Full Text] [Related]
10. Management of bisphosphonate-induced osteonecrosis of the jaw. Schilling J. Northwest Dent; 2008 Jan; 87(3):34-5, 37-8, 40. PubMed ID: 18663869 [Abstract] [Full Text] [Related]
11. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. Marx RE, Sawatari Y, Fortin M, Broumand V. J Oral Maxillofac Surg; 2005 Nov; 63(11):1567-75. PubMed ID: 16243172 [Abstract] [Full Text] [Related]
12. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, Kogan R. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Sep; 106(3):389-91. PubMed ID: 18554944 [Abstract] [Full Text] [Related]
18. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. Carlson ER, Basile JD. J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):85-95. PubMed ID: 19371819 [Abstract] [Full Text] [Related]
19. Bisphosphonate-induced osteonecrosis of the jaw: a medical enigma? Siddiqi A, Payne AG, Zafar S. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Sep; 108(3):e1-8. PubMed ID: 19570696 [Abstract] [Full Text] [Related]